Last updated on June 2019

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema


Brief description of study

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Clinical Study Identifier: NCT03622593

Find a site near you

Start Over

California Retina Consultants

Bakersfield, CA United States
  Connect »

The Retina Partners

Encino, CA United States
  Connect »

South Coast Retina Center

Los Angeles, CA United States
  Connect »

USC Roski Eye Institute

Los Angeles, CA United States
  Connect »

Doheny Eye Institute

Pasadena, CA United States
  Connect »

Retinal Consultants Med Group

Sacramento, CA United States
  Connect »

California Retina Consultants

Santa Barbara, CA United States
  Connect »

Bay Area Retina Associates

Walnut Creek, CA United States
  Connect »

Retina Consultants of Southern

Colorado Springs, CO United States
  Connect »

Retina Group of Florida

Fort Lauderdale, FL United States
  Connect »

Florida Eye Associates

Melbourne, FL United States
  Connect »

Bascom Palmer Eye Institute

Palm Beach Gardens, FL United States
  Connect »

Fort Lauderdale Eye Institute

Plantation, FL United States
  Connect »

Retina Vitreous Assoc of FL

Saint Petersburg, FL United States
  Connect »

Southeast Retina Center

Augusta, GA United States
  Connect »

Central Plains Eye MDs

Wichita, KS United States
  Connect »

Lahey Clinic Med Ctr

Lexington, KY United States
  Connect »

Retina Specialists

Towson, MD United States
  Connect »

Associated Retinal Consultants

Grand Rapids, MI United States
  Connect »

Vitreo-Retinal Associates

Grand Rapids, MI United States
  Connect »

Retina Associates of St. Louis

Florissant, MO United States
  Connect »

Retina Consultants of Nevada

Las Vegas, NV United States
  Connect »

Retina Center of New Jersey

Bloomfield, NJ United States
  Connect »

Long Is. Vitreoretinal Consult

Hauppauge, NY United States
  Connect »

New York University

New York, NY United States
  Connect »

Retina Assoc of Western NY

Rochester, NY United States
  Connect »

Ophthalmic Cons of Long Island

Rockville Centre, NY United States
  Connect »

The Retina Consultants

Slingerlands, NY United States
  Connect »

Scheie Eye Institute

Philadelphia, PA United States
  Connect »

Palmetto Retina Center

Florence, SC United States
  Connect »

Southeastern Retina Associates

Knoxville, TN United States
  Connect »

Tennessee Retina PC

Nashville, TN United States
  Connect »

Austin Retina Associates

Austin, TX United States
  Connect »

Retina Center of Texas

Grapevine, TX United States
  Connect »

Rocky Mountain Retina

Salt Lake City, UT United States
  Connect »

Univ of Virginia Ophthalmology

Charlottesville, VA United States
  Connect »

Retina Institute of Virginia

Richmond, VA United States
  Connect »

Retina Center Northwest

Silverdale, WA United States
  Connect »

Oftalmos

Capital Federal, Argentina
  Connect »

Oftar

Mendoza, Argentina
  Connect »

Sydney West Retina

Westmead, Australia
  Connect »

GO Giunta

Sherbrooke, QC Canada
  Connect »

Oculo Vision

Sherbrooke, QC Canada
  Connect »

Seoul St Mary's Hospital

Seoul, Korea, Republic of
  Connect »

UMC St Radboud

Nijmegen, Netherlands
  Connect »

Retina Group of New England

Waterford, CT United States
  Connect »

Asan Medical Center.

Seoul, Korea, Republic of
  Connect »

Retina Consultants Of Carolina

Greenville, SC United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Prairie Retina Center

Springfield, IL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.